Want to see SHTDY full AI Analyst Report?
Top Page
Sinopharm Group Co
(OTC:SHTDY)
Select Model
Select Model
Rating:60Neutral
Price Target:
$11.00
▼(-16.22% Downside)
Action:Downgraded
Date:04/26/26
The score is supported mainly by attractive valuation (very low P/E and a ~3.86% dividend yield). This is tempered by weakening financial performance (softening revenue, margin compression, and higher leverage) and bearish technical momentum (price below key moving averages with negative MACD and weak RSI).
Positive Factors
Extensive distribution network
A broad national logistics and sales footprint is a durable competitive advantage for a pharmaceutical distributor. Scale and reliable fulfillment lower per-unit costs, improve supplier access and contract wins, and support stable order flow from hospitals and pharmacies over the medium term.
Negative Factors
Weakening revenue and margins
Declining top-line and compressed margins indicate structural pressure on pricing and product mix. Reduced operating leverage limits reinvestment into logistics and retail expansion, weakens ability to absorb costs, and will pressure profitability and ROE over the coming months.
Read all positive and negative factors
Positive Factors
Negative Factors
Extensive distribution network
A broad national logistics and sales footprint is a durable competitive advantage for a pharmaceutical distributor. Scale and reliable fulfillment lower per-unit costs, improve supplier access and contract wins, and support stable order flow from hospitals and pharmacies over the medium term.
Read all positive factors
Sinopharm Group Co (SHTDY) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$6.99B
Dividend Yield3.75%
Average Volume (3M)1.38K
Price to Earnings (P/E)6.6
Beta (1Y)0.16
Revenue Growth-1.48%
EPS Growth1.66%
CountryUS
Employees94,910
SectorHealthcare
Sector Strength45
IndustryMedical - Distribution
Share Statistics
EPS (TTM)11.35
Shares Outstanding268,362,150
10 Day Avg. Volume773
30 Day Avg. Volume1,375
Financial Highlights & Ratios
PEG Ratio-4.41
Price to Book (P/B)0.64
Price to Sales (P/S)0.10
P/FCF Ratio4.32
Enterprise Value/Market Cap13.20
Enterprise Value/Revenue0.16
Enterprise Value/Gross Profit2.23
Enterprise Value/Ebitda4.40
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Sinopharm Group Co Business Overview & Revenue Model
Company Description
Sinopharm Group Co. Ltd. is a prominent Chinese enterprise specializing in the wholesale and retail of pharmaceuticals, medical devices, and other healthcare products. The company's diverse operations are structured into four key segments. The Pha...
How the Company Makes Money
Sinopharm makes money mainly by distributing and selling pharmaceuticals and healthcare products across China. Its core revenue stream is pharmaceutical distribution (wholesale), where it purchases drugs and other medical products from manufacture...
Sinopharm Group Co Financial Statement Overview
Summary
Income Statement
56
Neutral
Balance Sheet
52
Neutral
Cash Flow
60
Neutral
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 559.50B | 584.51B | 596.57B | 552.15B | 521.05B |
| Gross Profit | 40.09B | 44.26B | 48.51B | 47.43B | 44.05B |
| EBITDA | 20.38B | 20.17B | 26.90B | 26.25B | 24.68B |
| Net Income | 6.96B | 7.05B | 9.05B | 8.53B | 7.76B |
Balance Sheet | |||||
| Total Assets | 390.61B | 392.83B | 383.39B | 364.78B | 335.41B |
| Cash, Cash Equivalents and Short-Term Investments | 61.60B | 54.31B | 63.81B | 55.22B | 43.54B |
| Total Debt | 108.65B | 76.39B | 73.78B | 69.59B | 68.37B |
| Total Liabilities | 256.36B | 266.14B | 263.08B | 254.71B | 235.76B |
| Stockholders Equity | 84.01B | 78.88B | 74.58B | 68.07B | 61.89B |
Cash Flow | |||||
| Free Cash Flow | 12.52B | 9.58B | 14.84B | 18.55B | 7.05B |
| Operating Cash Flow | 14.14B | 11.55B | 17.17B | 20.96B | 9.31B |
| Investing Cash Flow | -963.89M | -3.75B | -944.53M | -3.59B | -1.27B |
| Financing Cash Flow | -18.69B | -17.29B | -7.64B | -5.69B | -14.69B |
Sinopharm Group Co Technical Analysis
Neutral
13.13
Price Trends
10.64
Positive
11.58
Negative
11.99
Negative
Market Momentum
0.16
Negative
61.02
Neutral
92.79
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SHTDY, the sentiment is Neutral. The current price of 13.13 is above the 20-day moving average (MA) of 10.52, above the 50-day MA of 10.64, and above the 200-day MA of 11.99, indicating a neutral trend. The MACD of 0.16 indicates Negative momentum. The RSI at 61.02 is Neutral, neither overbought nor oversold. The STOCH value of 92.79 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for SHTDY.
Sinopharm Group Co Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
70 Outperform | $2.36B | 12.67 | 10.29% | ― | -4.31% | -8.94% | |
65 Neutral | $98.51B | 21.78 | -265.44% | 0.37% | 12.36% | 48.80% | |
63 Neutral | $53.52B | 34.84 | -55.72% | 0.98% | 12.80% | 2.04% | |
62 Neutral | $59.91B | 23.47 | 115.93% | 0.66% | 5.95% | 51.04% | |
60 Neutral | $6.99B | 6.64 | 8.70% | 3.75% | -1.48% | 1.66% | |
60 Neutral | $10.00B | 26.29 | 11.86% | ― | 5.64% | 2.92% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
SHTDY
Sinopharm Group Co
11.21
-0.29
-2.51%
COR
Cencora
307.90
17.42
6.00%
CAH
Cardinal Health
228.52
71.57
45.60%
HSIC
Henry Schein
87.82
18.75
27.15%
MCK
McKesson
841.39
133.06
18.79%
PBH
Prestige Consumer Healthcare
49.92
-25.64
-33.93%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.